Cover Image
Market Research Report

Consensus Outlook: Multiple Sclerosis

Published by FirstWord Product code 251331
Published Content info
Delivery time: 1-2 business days
Back to Top
Consensus Outlook: Multiple Sclerosis
Published: September 26, 2012 Content info:


Charting the Future Multiple Sclerosis Market Landscape


Over the next five years, the global multiple sclerosis (MS) market is set to grow from $12.3 billion in 2011 to $17.3 billion in 2016. Primary drivers of this growth will be the entry of new pipeline therapies, satisfying the unmet needs of convenient administration and more efficacious therapy, and continued uptake of existing therapies.

Therapy Trends Consensus Outlook: Multiple Sclerosis analyses the global MS market players and products of today and tomorrow. Start mapping your market parameters with access to the following comprehensive resources:

  • An in-depth 5-year forecast report based on analyst consensus, mapping the impact of future events to predicted product performance
  • A detailed forecast data analysis spreadsheet model comparing critical market parameters including market size, product sales, market shares and competitive status over the period 2006 to 2016
  • Timely event-driven market forecast report and data analysis updates over the next 12 months
Table of Contents
Product Code: 400200130

Table of Contents

  • FirstWord Analysis Highlights
  • Research Methodology
  • Multiple Sclerosis Marketplace
  • Key Multiple Sclerosis Developers
  • Multiple Sclerosis Class Dynamics
  • Gilenya (fingolimod; Novartis Mitsubishi Tanabe) Forecast
  • Tysabri (natalizumab; Biogen/Elan) Forecast
  • Copaxone (glatiramer acetate; Teva) forecast
  • Avonex (interferon beta-1a; Biogen) Forecast
  • Betaseron (interferon beta-1b; Bayer) Forecast
  • Rebif (interferon beta-1a; Merck) Forecast
  • Extavia (interferon beta-1b; Novartis) Forecast
  • BG-12 (dimethyl fumarate; Biogen) Forecast
  • Aubagio (teriflunomide; Sanofi) Forecast
  • Laquinimod (Teva/Active Biotech) Forecast
  • Lemtrada (alemtuzumab; Genzyme/Sanofi) Forecast
  • Daclizumab HYP (Biogen/Abbott) Forecast
  • Ocrelizumab (Biogen/Roche/Biogen) Forecast
  • Appendix
Back to Top